Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:00:31.126Z.
Calculation as of: 2026-10-06T18:00:31.126Z.
Quote observation: 2026-10-06T18:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.53M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.32M
PS Ratio
N/A
TTM Avg
46.19
3Y Avg
46.23
5Y Avg
46.23
Market Cap
$111.92M
PS Ratio
3.05
TTM Avg
11.54
3Y Avg
10.77
5Y Avg
81.00
Market Cap
$107.09M
PS Ratio
N/A
TTM Avg
119.38
3Y Avg
60.79
5Y Avg
244.46
Market Cap
$106.98M
PS Ratio
3.42
TTM Avg
1.84
3Y Avg
1.24
5Y Avg
1.12
Market Cap
$112.53M
PS Ratio
67.38
TTM Avg
60.78
3Y Avg
38.49
5Y Avg
33.17
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.53M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.74M | 1.88 | 2.94 | 1.80 | 3.05 |
| Immunic, Inc. (IMUX)vs › | $107.47M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.32M | N/A | 46.19 | 46.23 | 46.23 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.92M | 3.05 | 11.54 | 10.77 | 81.00 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | N/A | 119.38 | 60.79 | 244.46 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 3.42 | 1.84 | 1.24 | 1.12 |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | 151.10 | 76.56 | 65.08 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.53M | 67.38 | 60.78 | 38.49 | 33.17 |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | N/A | 30.26 | 25.91 | 25.91 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-23 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
